Videos

Here is a summary of our coverage from EHA25 Virtual, the annual meeting for the European Hematology Association (EHA).

Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines (AAM) discusses potential legislation that the AAM is advocating for and how the upcoming election and Supreme Court decision will affect biosimilars.

Here are the top 5 biosimilars articles for the week of June 8, 2020.

Joseph P. Fuhr Jr, PhD, professor emeritus of economics at Widener University in Chester, Pennsylvania, and an expert on antitrust health economics and pharmacoeconomics discusses how future biosimilar competition will affect consumers and market development.

Here are the top 5 biosimilars articles for the week of June 1, 2020.

An extended interview with Ha Kung Wong, JD, an intellectual property law attorney and partner at Venable Fitzpatrick in New York and April Breyer Menon, JD, an expert on biosimilar patent law and founder of April Breyer Consulting in Chicago discussing potential biosimilars legislation.

Here is a summary of our coverage from ASCO20 Virtual, the annual meeting for the American Society of Clinical Oncology (ASCO).

Here are the top 5 biosimilars articles for the week of May 25, 2020.

Ali McBride, PharmD, MS, BCOP, clinical coordinator of Hematology and Oncology in the Department of Pharmacy at the University of Arizona Cancer Center and past president of the Association of Community Cancer Centers (ACCC), discusses physician struggles tied to biosimilar utilization, the upcoming initiatives for the ACCC Biosimilars Center, and why physicians should be keeping an eye on biosimilars.

Here are the top 5 biosimilars articles for the week of May 18, 2020.

Roman Drai, MD, PhD, deputy director and head of clinical operations at Geropharm, discusses how Russia has developed its biopharmaceuticals industry.

Ali McBride, PharmD, MS, BCOP, clinical coordinator of Hematology and Oncology in the Department of Pharmacy at the University of Arizona Cancer Center and past president of the Association of Community Cancer Centers (ACCC), discusses the anticipated growth for the US biosimilar market and what the ACCC is doing to further uptake efforts.

Here are the top 5 biosimilars articles for the week of May 11, 2020.

Jim M. Koeller, MS, a professor of pharmacotherapy and member of the Center for Pharmacoeconomic Studies in the College of Pharmacy at the University of Texas at Austin, discusses the complexities of an institution taking on multiple biosimilars and how payers can make the process easier.